Merlin Biotech
PrivateLast Round
Seed Round
Aug 11, 2026
Total Funding Raised
$1M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Merlin Biotech is a biotechnology company that develops novel mRNA-based therapeutics and vaccines for oncology, chronic hepatitis B, and Lyme disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Merlin Biotech Comparables
Compare Merlin Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Strand Therapeutics | 77% | |
| RNAimmune | 76% | |
| Replicate Bioscience | 76% |
Merlin Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Aug 11, 2026 | ||||
| Seed | Feb 11, 2025 | ||||
| Seed | Jan 25, 2024 | ||||
| Debt | Nov 2, 2023 | ||||
| Debt | Jan 5, 2023 | ||||
Accelerator | Dec 1, 2022 |
Merlin Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Alliance for Health Equity | Seed |
| Commonwealth of Pennsylvania | Grant |
| Startup Bucks | Accelerator, Seed |
| Bucks County Industrial Development Authority | Debt, Accelerator, Seed |
| Bucks Built Startup Fund | Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 11, 2026
$50K raised in Seed Round.
- Feb 11, 2025
$100K raised from The Alliance for Health Equity.
Recent news
Latest coverage and updates
- is_developingOct 6, 2026
MERLIN Biotech, LLC. develops MER-101, an mRNA-based immunotherapy, for Ewing sarcoma under an earlier NIH contract, while a Phase I SBIR grant extends the program to head and neck cancer in Pennsylvania on Oct 6th '26.
- receives_financingOct 6, 2026
MERLIN Biotech, LLC. receives a $400K Phase I SBIR grant from the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health, on Oct 6th '26 in Pennsylvania to investigate MER-101 in head and neck cancer.
Merlin Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Merlin Biotech's valuation, stock price, and market status.
Is Merlin Biotech a public or private company?
Merlin Biotech is a private company.
What is the current stock price of Merlin Biotech?
Merlin Biotech is a private company, so its shares have no public market price. Caplight tracks Merlin Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Merlin Biotech worth (valuation)?
Valuation information for Merlin Biotech is not publicly available.
Can I buy Merlin Biotech stock?
Merlin Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Merlin Biotech's last funding round?
Merlin Biotech's most recent funding round was Seed Round on August 11, 2026.
Who are the main investors in Merlin Biotech?
Key investors in Merlin Biotech include The Alliance for Health Equity, Commonwealth of Pennsylvania, Startup Bucks, Bucks County Industrial Development Authority, Bucks Built Startup Fund.
Will Merlin Biotech IPO soon?
No public IPO plans have been announced for Merlin Biotech.
How can I track Merlin Biotech secondary market activity?
Caplight tracks bids, offers, and trades in Merlin Biotech's shares on secondary markets.